Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LORFAN vs ENTEREG
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lorlatinib is an ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It inhibits phosphorylation of ALK and ROS1, leading to apoptosis and cell cycle arrest.
Selective 5-HT4 receptor agonist; enhances gastrointestinal motility by increasing peristalsis and accelerating colonic transit.
FDA-approved for treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on prior ALK inhibitors,Off-label: ROS1-positive metastatic NSCLC
FDA-approved for the treatment of chronic idiopathic constipation in adults
12 mg orally three times daily; titrate to 24 mg twice daily after 14 days based on response and tolerability.
Adults: 12 mg orally twice daily for up to 15 days, initiated within 30 minutes prior to surgery and continued postoperatively.
Terminal elimination half-life is 2-3 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours in severe impairment).
Terminal half-life is approximately 10–17 hours in healthy subjects. Clinically, the half-life may be prolonged in severe hepatic impairment but is not significantly altered in renal impairment.
Primarily metabolized by CYP3A4 and UGT1A4. Lorlatinib is a substrate of P-glycoprotein.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4); also involves CYP2D6 and CYP2C9 to a lesser extent.
Primarily renal excretion (90-95% as unchanged drug); minimal biliary/fecal elimination (<5%).
Primarily hepatobiliary excretion; unchanged drug and major metabolite (alvimopan) undergo extensive biliary elimination with fecal excretion accounting for >90% of total elimination. Renal excretion is minimal (<5% as unchanged drug).
Approximately 20-30% bound to plasma proteins, primarily albumin.
Approximately 80–90% bound to plasma proteins, primarily albumin.
2.0-3.0 L/kg, indicating extensive distribution into tissues.
Volume of distribution is about 30 L (approximately 0.4 L/kg), indicating distribution into extracellular fluid and tissues.
Subcutaneous: approximately 80-100%; intramuscular: approximately 80%; intravenous: 100%.
Oral bioavailability is approximately 6–10% due to extensive first-pass metabolism; the drug is administered orally for local gastrointestinal activity.
No adjustment required for GFR ≥ 30 m L/min; avoid use if GFR < 30 m L/min.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) or dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce to 12 mg once daily; Child-Pugh Class C: not recommended.
No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Caution in severe hepatic impairment (Child-Pugh C); no specific dose recommendation.
Not established for age < 18 years.
Not FDA-approved for pediatric patients; safety and efficacy not established.
No specific dose adjustment; monitor renal function and tolerability closely due to age-related decline in renal function.
No specific dose adjustment; use with caution due to potential increased sensitivity and renal function decline. Monitor for adverse effects.
None.
No FDA boxed warning.
Hepatotoxicity: Monitor liver enzymes monthly for first 3 months, then periodically.,Interstitial lung disease/pneumonitis: Withhold and evaluate.,Hyperlipidemia: Monitor serum cholesterol and triglycerides; manage with lipid-lowering agents.,CNS effects: Including seizure, hallucinations, cognitive impairment; dose adjust or withhold.,AV block: Monitor ECG; withhold in second- or third-degree AV block.,Fetal harm: Can cause fetal harm; advise effective contraception.
May cause diarrhea, leading to electrolyte disturbances or hypovolemia,Use with caution in patients with severe renal impairment,Avoid use in patients with a history of mechanical gastrointestinal obstruction, perforation, or severe inflammatory bowel disease
Concomitant use of strong CYP3A4 inducers,Concomitant use of strong CYP3A4 inhibitors (avoid, or reduce dose if unavoidable)
Hypersensitivity to prucalopride or any excipients,Renal impairment requiring dialysis,Intestinal obstruction or perforation
Take on empty stomach with water only. Must follow a low-fat diet (<20% of total calories from fat) throughout treatment. Avoid grapefruit and grapefruit juice (CYP3A4 inhibition). Avoid alcohol due to hepatotoxicity risk.
No specific food interactions reported. However, as ENTEREG is administered in a hospital setting, patients should follow the prescribed diet (typically clear liquids advancing to regular diet as tolerated postoperatively). Avoid grapefruit juice as it may affect drug metabolism via CYP3A4 (though not specifically studied, caution is advised).
Lorlatinib is embryotoxic and fetotoxic in animal studies. In pregnant rats, malformations (including cardiovascular and skeletal) and fetal growth restriction observed at maternal exposures below human AUC. No human data. Avoid in pregnancy; if used, advise effective contraception.
No human data; animal studies at doses up to 10 mg/kg/day in rats and rabbits showed no teratogenicity at exposures lower than human dose; risk cannot be excluded due to lack of adequate human studies.
No human data on lorlatinib in breast milk. Animal studies show excretion in rat milk. M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, advise not to breastfeed during treatment and for at least 11 days after last dose.
No data on presence in human milk; caution advised; M/P ratio unknown.
Physiologic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism) may reduce lorlatinib exposure. Monitor therapeutic response and toxicity. Consider dose adjustment based on tolerability (increase if subtherapeutic, but safety not established). No specific dose recommendations due to lack of human data; hold if severe toxicity.
No pharmacokinetic studies in pregnancy; dose adjustment not required based on available data.
LORFAN (lomitapide) is a microsomal triglyceride transfer protein inhibitor used for homozygous familial hypercholesterolemia. Monitor hepatic function monthly due to risk of elevated transaminases and hepatic steatosis. Must be taken with a low-fat diet (<20% of calories from fat) to reduce gastrointestinal adverse effects. Concomitant use with strong CYP3A4 inhibitors is contraindicated. Dose adjustments needed with moderate CYP3A4 inhibitors. Administer with water only, no food, at least 2 hours after evening meal and 2 hours before next meal.
ENTEREG (alvimopan) is a peripherally acting mu-opioid receptor antagonist indicated to accelerate postoperative recovery of GI function after bowel resection surgery. It does not cross the blood-brain barrier, so it does not reverse opioid analgesia. Use is restricted to hospitalized patients; it should not be used for more than 7 days. Contraindicated in patients who have taken therapeutic doses of opioids for >7 consecutive days immediately prior to initiation, as it may precipitate opioid withdrawal. Monitor for GI adverse effects such as nausea, vomiting, and abdominal pain.
Take lomitapide with a low-fat diet; avoid high-fat meals to reduce stomach side effects.,Take the medication with a glass of water only, at least 2 hours after your evening meal and 2 hours before your next meal.,Do not eat grapefruit or drink grapefruit juice while taking this medication.,Inform your doctor immediately if you experience yellowing of eyes/skin, dark urine, or abdominal pain.,You will need regular blood tests to check liver function; do not miss these appointments.,Avoid alcohol consumption during treatment.
Take ENTEREG exactly as prescribed; do not take more than the recommended dose.,This medication is used only in the hospital after bowel surgery to help your bowels start working again.,It does not reduce pain or interfere with your pain medication.,Report any severe abdominal pain, nausea, vomiting, or diarrhea to your healthcare provider.,Do not take this medication if you have recently taken opioid pain medications for more than 7 days in a row.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LORFAN vs ENTEREG, answered by our medical review team.
LORFAN is a Opioid antagonist that works by Lorlatinib is an ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It inhibits phosphorylation of ALK and ROS1, leading to apoptosis and cell cycle arrest.. ENTEREG is a Peripheral Opioid Antagonist that works by Selective 5-HT4 receptor agonist; enhances gastrointestinal motility by increasing peristalsis and accelerating colonic transit.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LORFAN and ENTEREG depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LORFAN is: 12 mg orally three times daily; titrate to 24 mg twice daily after 14 days based on response and tolerability.. The standard adult dose of ENTEREG is: Adults: 12 mg orally twice daily for up to 15 days, initiated within 30 minutes prior to surgery and continued postoperatively.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LORFAN and ENTEREG in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LORFAN is classified as Category C. Lorlatinib is embryotoxic and fetotoxic in animal studies. In pregnant rats, malformations (including cardiovascular and skeletal) and fetal growth restriction observed at maternal. ENTEREG is classified as Category C. No human data; animal studies at doses up to 10 mg/kg/day in rats and rabbits showed no teratogenicity at exposures lower than human dose; risk cannot be excluded due to lack of ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.